Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Charles Elson MD

Charles O. Elson MD

Professor of Medicine, Microbiology, and Surgery and Basil I. Hirschowitz Chair in Gastroenterology, University of Alabama at Birmingham, Birmingham, Alabama

Dr. Elson is Professor of Medicine, Microbiology, and Surgery at the University of Alabama at Birmingham and holds the Basil I. Hirschowitz Chair in Gastroenterology. He is an active consultant in immune-mediated intestinal disorders. The central focus of the Elson laboratory is on the regulation of mucosal immune responses, particularly the mucosal immune response to the microbiota. His group discovered that microbiota flagellins from the Lachnospiraceae family, an abundant member of the microbiota, were immunodominant antigens in experimental colitis and in Crohn’s disease. He and co-workers generated a CBir1 flagellin T cell receptor transgenic mouse that has provided important insights into host immune-microbiota interactions.


Dr. Elson discloses the following: UAB and I hold a patent on flagellin 2 of A4 bacteria, which has been licensed to Prometheus Laboratories for clinical use.